Effect of Statins, Metformin, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers on Age-Related Macular Degeneration

Lee, Hyesung; Jeon, Ha‐Lim; Park, Sang Jun; Shin, Ju Young

doi:10.3349/ymj.2019.60.7.679

Cited by 32 publications

(73 citation statements)

References 26 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lipid-lowering drug simvastatin, which a 3-hydroxy-3-methylglutaryl-CoA reductase antagonist, is widely employed to reduce cholesterol biosynthesis and to reduce coronary artery disease events in subjects with or without diagnosed cardiovascular disease [168]. The beneficial effect of simvastatin on the cardiovascular system is strengthened by its documented ability to stimulate angiogenesis [169], trigger endothelium-dependent NO release [170,171], and improve left ventricular ejection fraction (LVEF) in heart failure [172].…”

Section: Chemical Stimulation Of Trpv1 Promotes Angiogenesis In a Ca mentioning

confidence: 99%

Endothelial TRPV1 as an Emerging Molecular Target to Promote Therapeutic Angiogenesis

Negri

Faris

Rosti

et al. 2020

Cells

View full text Add to dashboard Cite

Therapeutic angiogenesis represents an emerging strategy to treat ischemic diseases by stimulating blood vessel growth to rescue local blood perfusion. Therefore, injured microvasculature may be repaired by stimulating resident endothelial cells or circulating endothelial colony forming cells (ECFCs) or by autologous cell-based therapy. Endothelial Ca2+ signals represent a crucial player in angiogenesis and vasculogenesis; indeed, several angiogenic stimuli induce neovessel formation through an increase in intracellular Ca2+ concentration. Several members of the Transient Receptor Potential (TRP) channel superfamily are expressed and mediate Ca2+-dependent functions in vascular endothelial cells and in ECFCs, the only known truly endothelial precursor. TRP Vanilloid 1 (TRPV1), a polymodal cation channel, is emerging as an important player in endothelial cell migration, proliferation, and tubulogenesis, through the integration of several chemical stimuli. Herein, we first summarize TRPV1 structure and gating mechanisms. Next, we illustrate the physiological roles of TRPV1 in vascular endothelium, focusing our attention on how endothelial TRPV1 promotes angiogenesis. In particular, we describe a recent strategy to stimulate TRPV1-mediated pro-angiogenic activity in ECFCs, in the presence of a photosensitive conjugated polymer. Taken together, these observations suggest that TRPV1 represents a useful target in the treatment of ischemic diseases.

show abstract

Section: Chemical Stimulation Of Trpv1 Promotes Angiogenesis In a Ca mentioning

confidence: 99%

Endothelial TRPV1 as an Emerging Molecular Target to Promote Therapeutic Angiogenesis

Negri

Faris

Rosti

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

“…Statins are used to treat high cholesterol in patients at risk for CVD and are one of the most prevalent prescriptions, with 28% of adults over 40 taking statins in 2012 [ 103 ]. Many diabetic and pre-diabetic patients take statins and are at risk for different age-related eye diseases, but the association of statin use and AMD is inconclusive [ 104 , 105 ]. Information surrounding statin use and cataracts is also inconclusive: of three meta-analyses of observational and randomized controlled trials for statins and cataracts, one reported reduced risk for cataract, one reported a mild increased risk, and the third was inconclusive [ 106 , 107 , 108 ].…”

Section: Future Directions For Nutrition and Age-related Eye Diseamentioning

confidence: 99%

Dietary Patterns, Carbohydrates, and Age-Related Eye Diseases

et al. 2020

View full text Add to dashboard Cite

Over a third of older adults in the U.S. experience significant vision loss, which decreases independence and is a biomarker of decreased health span. As the global aging population is expanding, it is imperative to uncover strategies to increase health span and reduce the economic burden of this age-related disease. While there are some treatments available for age-related vision loss, such as surgical removal of cataracts, many causes of vision loss, such as dry age-related macular degeneration (AMD), remain poorly understood and no treatments are currently available. Therefore, it is necessary to better understand the factors that contribute to disease progression for age-related vision loss and to uncover methods for disease prevention. One such factor is the effect of diet on ocular diseases. There are many reviews regarding micronutrients and their effect on eye health. Here, we discuss the impact of dietary patterns on the incidence and progression of age-related eye diseases, namely AMD, cataracts, diabetic retinopathy, and glaucoma. Then, we focus on the specific role of dietary carbohydrates, first by outlining the physiological effects of carbohydrates on the body and then how these changes translate into eye and age-related ocular diseases. Finally, we discuss future directions of nutrition research as it relates to aging and vision loss, with a discussion of caloric restriction, intermittent fasting, drug interventions, and emerging randomized clinical trials. This is a rich field with the capacity to improve life quality for millions of people so they may live with clear vision for longer and avoid the high cost of vision-saving surgeries.

show abstract

“…A nested case–control study on AMD patients was conducted recently by Lee et al. 25 using the information available on the Korean National Health Insurance Service database. The study suggested that ACE inhibitors and angiotensin receptor blockers (ARBs) did not inhibit AMD in elderly patients.…”

Section: Degeneration Of the Ecmmentioning

confidence: 99%

“…The study suggested that ACE inhibitors and angiotensin receptor blockers (ARBs) did not inhibit AMD in elderly patients. 25…”

Section: Degeneration Of the Ecmmentioning

confidence: 99%

Bruch’s membrane pathology: A mechanistic perspective

Murali¹,

Krishnakumar²,

Subramanian

et al. 2020

European Journal of Ophthalmology

View full text Add to dashboard Cite

Bruch’s membrane, an extracellular matrix located between the retinal pigment epithelium and the choroid, plays a vital role as structural and functional support to the retinal pigment epithelium. Dysfunction of Bruch’s membrane in both age-related macular degeneration and other ocular diseases is caused mostly by extracellular matrix degeneration, deposit formation, and angiogenesis. Although these factors are dealt in greater detail with respect to the cells that are degenerated such as the retinal pigment epithelium and the endothelial cells, the pathology involving the Bruch’s membrane is often underrated. Since in most of the macular degenerations early degenerative changes are also observed in the Bruch’s membrane, addressing only the cellular component without the underlying membrane will not yield an ideal clinical benefit. This review aims to discuss the factors and the mechanisms affecting the integrity of the Bruch’s membrane, which would aid in developing an effective therapy for these pathologies.

show abstract

Effect of Statins, Metformin, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers on Age-Related Macular Degeneration

Cited by 32 publications

References 26 publications

Endothelial TRPV1 as an Emerging Molecular Target to Promote Therapeutic Angiogenesis

Endothelial TRPV1 as an Emerging Molecular Target to Promote Therapeutic Angiogenesis

Dietary Patterns, Carbohydrates, and Age-Related Eye Diseases

Bruch’s membrane pathology: A mechanistic perspective

Contact Info

Product

Resources

About